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Abstract
Background: Blinding is a measure in randomized controlled trials (RCT) to reduce detection and performance bias.
There is evidence that lack of blinding leads to overestimated treatment effects. Because of the physical component of
interventions, blinding is not easily applicable in surgical trials. This is a protocol for a systematic review and empirical
study about actual impact on outcomes and future potential of blinding in general and abdominal surgery RCT.
Methods/design: A systematic literature search in CENTRAL, MEDLINE and Web of Science will be conducted to locate
RCT between 1996 and 2015 with a surgical intervention. General study characteristics and information on blinding
methods will be extracted. The risk of performance and detection bias will be rated as low, unclear or high according
to the Cochrane Collaboration’s tool for assessing risk of bias. The main outcome of interest will be the association of a
high risk of performance or detection bias with significant trial results and will be tested at a level of significance of
5 %. Further, trials will be meta-analysed in a Mantel-Haenszel model comparing trials with high risk of bias to other
trials at a level of significance of 5 %.
Discussion: Detection and performance bias distort treatment effects. The degree of such bias in general and
abdominal surgery is unknown. Evidence on influence of missing blinding would improve critical appraisal and
conduct of general and abdominal surgery RCT.
Systematic review registration: PROSPERO 2015:CRD42015026837.
Keywords: Blinding, Bias, Performance bias, Detection bias, Risk of bias, General and abdominal surgery, Randomized
controlled trial, Systematic review
Background
The aim of evidence-based medicine is to find the opti-
mal treatment for patients. This process is based on the
expertise of the treating practitioner, the characteristics
of patients and the best available external evidence [1]. If
available, the best external evidence is data from proper
conducted randomized controlled trials (RCT) [2]. Prop-
erly conducted RCT take several measures to minimize
bias in order to get valid conclusions [3].
Bias describes a systematic error which leads to
deviation of the measured effect away from the true
effect of an intervention [4]. The Cochrane Collabor-
ation defined the following standard domains of bias:
random sequence generation, allocation sequence con-
cealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome
data, selective outcome reporting and others. These
domains are part of critical appraisal in order to judge
validity of trials. Influence of bias on quantitative
results can be revealed when conducting sensitivity
analyses [4]. The CONSORT statement (Consolidated
Standards of Reporting Trials), a guideline on reporting
of outcomes in randomized controlled trials, declared
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the information to evaluate these domains of bias as
mandatory [5].
One measure to reduce bias is blinding. The risk that
awareness of the applied intervention bias effects is called
performance bias. Blinding of participants and personnel
reduces performance bias. A patient or practitioner who
trusts in the effect of a specific intervention may uncon-
sciously or intentionally perceive or detect an enhanced
treatment effect [4]. The common term “double-blinded”
refers to full avoidance of performance bias by blinding
both participants and personnel [6]. Detection bias refers
to the risk of how the evaluation of the outcome bias
effects. Blinding of outcome assessors reduces detection
bias. Outcome assessors (study nurses or investigators)
who are aware of the actual treatment may unconsciously
or intentionally alter their assessment. Particularly, in case
of soft endpoints, e.g. pain blinding of outcome assessors
is important. For hard comparators like mortality detec-
tion bias is irrelevant [4, 7].
To express bias quantitatively, the association of
lack of blinding and significant results is expressed as
an odds ratio. From other medical disciplines, four
empirical studies [8–11] exist on this topic. Each of
them compared the results of clinical trials with
absent versus present blinding. A meta-analysis of
these empirical studies showed an odds ratio of 0.86
(95 % confidence interval 0.74 to 0.99) demonstrating
that lack of blinding leads to overestimated treatment
effects [7]. Similarly, the degree of detection bias has
been investigated. Blinded and unblinded neurologists
assessed a medical intervention to treat multiple
sclerosis. Although, no treatment benefit was present,
the unblinded neurologists’ scores demonstrated an
apparent treatment benefit whereas the blinded neu-
rologists’ scores did not [12].
Due to the physical component of interventions, surgi-
cal RCT methodology has some specifics. Blinding of
the operating surgeon is sometimes impossible. Blinding
of patients and outcome assessors is not easily applicable
[3, 4, 13]. For several non-pharmacological treatments,
different blinding methods have been investigated, pro-
viding detailed methodological information about pos-
sible extent of blinding in surgery [14]. However, it
remains unclear if ornate blinding measures for surgical
interventions are really justified by the gain of better evi-
dence. Cancelling out the blinding measures of patients
due to the physical component is very probable and has
never been systematically investigated.
Until today, influence of detection and performance
bias in general and abdominal surgery RCT is unex-
plored. The objective of the planned systematic review
and empirical study is to investigate actual impact on
outcomes and future potential of blinding in general and
abdominal surgery RCT.
Methods/design
This protocol has been prospectively registered under
PROSPERO 2015:CRD42015026837 and is written
according to the PRISMA-P statement [15] which is
included as Additional file 1: PRISMA-P statement.
Research question
This study aims to determine the status, potential and
influence of blinding on outcomes in general and
abdominal surgery RCT.
The main outcome is the association of a high risk of
detection or performance bias with positive results in
general and abdominal surgery RCT.
Secondary outcomes are firstly, the difference of out-
comes comparing trials with high risk of bias to trials
with low or unclear risk of bias. Secondly, the present
status of blinding in general and abdominal surgery will
be evaluated by quantification of blinding measures and
their reporting in RCT since 1996. Thirdly, the potential
of blinding in surgical RCT determined as comparison
between possible and actual used blinding methods.
Systematic literature search
A research question was formulated according to the
PICO model (participants, interventions, comparisons
and outcomes) [4]. Figure 1 shows the PICO question
with the search strategy for MEDLINE (via PubMed).
The full search strategy is shown in Additional file 2:
Search strategy. The following databases will be
searched: CENTRAL, MEDLINE (via PubMed) and Web
of Science. A search strategy based on vocabulary the-
saurus (MeSH or Emtree) in combination with text
words will be used. The search will be limited starting
August 1996 when the first CONSORT statement [16]
was published and December 2015. No language restric-
tions will be applied.
Study selection
Abstract and full-text screening will be performed inde-
pendently by two reviewers following the recommenda-
tions of the Cochrane Collaboration [4]. Articles
gathered by the systematic literature search will be
screened for eligibility. Randomized controlled trials
from general and abdominal surgery with a surgical
(non-pharmacological intervention) in adult human
patients will be included into full-text screening. A sur-
gical intervention is characterized by a skin incision
and a dominant physical component and/or change of
anatomy. Good examples for surgical trials to be inves-
tigated are comparisons of two surgical accesses (e.g.
open vs. laparoscopic), strategies (e.g. Bassini vs. Shoul-
dice in groin surgery) or two possibilities for a specific
resection (e.g. hand vs. stapler anastomosis). Trials that
investigate surgical education, compare a surgical
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intervention with a non-surgical intervention (e.g.
pharmacologic or radiation) and compare early vs. late
time point for operation or more than two study arms
will be excluded.
A full-text screening will be performed for all articles
eligible after abstract screening. All trials will be checked
for proper randomization and allocation according to
the recommendations of the Cochrane Collaboration [4].
Moreover, RCT with an a priori defined primary end-
point and an intention-to-treat (ITT) analysis or without
unexplained dropout will be included into quantitative
analysis.
Including only trials with proper randomization and al-
location prevents a high risk of selection bias [4]. An a
priori defined primary endpoint is necessary in order to
have a sample in which trials are excluded with changed,
newly introduced or omitted primary endpoints which
therefore are at high risk of bias due to selective reporting
[17]. An endpoint is defined a priori if there is an open
accessible protocol defining the endpoint as reported or if
the primary endpoint is based on a sample size calcula-
tion. Including only trials with ITT analysis (with less than
10 % imputated data) or without unexplained dropout
prevents high risk of bias due to incomplete outcome data
(attrition bias) [4].
The rationale of the applied eligibility criteria is to
achieve a homogenous sample of trials set apart preferably
by one point, i.e. the investigated effect of detection and
performance bias (Fig. 2).
Data extraction
The following study characteristics will be extracted: title,
author, year of publication, journal, surgical speciality
(upper gastrointestinal surgery, hepato-pancreatico-biliary
surgery, colorectal surgery/proctology, endocrine surgery,
hernia, mixed, others), intervention and control interven-
tion, primary endpoint and outcome. Details of blinding
will be extracted from the publication of trials or pub-
lished protocols belonging to the trials: position in the art-
icle where blinding is mentioned (title, abstract, methods
section or separate protocol), presence, absence or non-
reporting of blinding of trial contributors (patients, practi-
tioners, data collectors, outcome assessors, data analysts),
feasibility of blinding trial contributors, risk of perform-
ance and detection bias (low, unclear, high), if the influ-
ence of missing blinding was discussed and if possible
unblinding was assessed during the trial. Funding source
is also extracted as another potential source of bias [18].
The original data extraction sheet is shown in Additional
file 3: Data extraction sheet.
Data extraction will be performed by two reviewers
independently for quality assurance purposes [19]. Dis-
crepancies between the two reviewers will be resolved by
a third reviewer, and a final extraction sheet will be
determined for database entry. After the last extraction
sheet is entered into the database, it will be closed and
made available for statistical analysis.
Data synthesis for the main outcome
Trials will be dichotomized whether they have a high
risk of bias due to missing blinding measures or not
(low and unclear risk of bias). This is considered to be
present if there is a high risk for detection bias or per-
formance bias. Risk for performance and detection bias
will be graded as low, unclear or high according to the
Cochrane Collaboration’s tool for assessing risk of bias
Fig. 1 PICO question and search strategy for MEDLINE (via PubMed)
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Fig. 2 Conceptual visualization of the included study sample
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[4]. As mentioned above, blinding is not always possible
in surgical trials. As an aid for judgement about feasibil-
ity of blinding trial contributors, the systematic review
of Boutron et al. will be used [14].
Further, trials will be dichotomized whether they have a
significant result or not at a level of significance of <5 %.
Statistical analysis
Primary statistical analysis and meta-analysis will be per-
formed with program R [20] and Revman 5.3.5 [21],
respectively.
Main outcome
The null hypothesis (H0) is that a high risk of perform-
ance or detection bias is not associated with significant
results. The alternative hypothesis (H1) is that a high
risk of performance or detection bias is associated with
significant results.
The main outcome will be evaluated for performance
and detection bias separately. A test at a level of signifi-
cance of 5 % on the association of high risk of bias and
significant results will be performed.
The significance of association will be tested by means
of Fisher’s exact test if at least one value in the contin-
gency table is 5 or below. Pearson’s chi-squared test with
Yates’s correction will be used if the total sample size is
60 or less. In all other cases, significance of association
will be tested using Pearson’s chi-squared test without
Yates’s correction [22].
Secondary outcomes
A separate meta-analysis for binary and continuous data
will be conducted with random-effects Mantel-Haenszel
model comparing the high risk of bias trials with the rest
of trials at a level of significance of 5 % for subgroup dif-
ference. Publication bias will be explored using a funnel
plot separately for trials at high risk and not at high risk.
The rate of blinded trials and respective blinded study
contributors will be expressed descriptively overall and
over time periods (1996–2000, 2001–2009, 2010–2015).
The potential of blinding will be expressed as compari-
son of actual blinded trials with feasibility of blinding in
included trials.
Subgroup and sensitivity analysis
For the main outcome and secondary outcomes, sub-
group analyses will be performed according to which
of the study contributors were blinded. Additionally, a
subgroup analysis will be performed according to the
intervention type in included trials, i.e. investigating
operative accesses, different instruments or surgical
strategies.
A sensitivity analysis of the main outcome will be per-
formed excluding all trials with an objective primary
endpoint, e.g. mortality. Furthermore, a sensitivity ana-
lysis for the main outcome will be performed comparing
trials at low risk of bias with high/unclear risk of bias
and comparing trials at high risk of bias with trials at
low risk of bias only.
Discussion
This protocol describes the methods of a systematic re-
view and empirical analysis, which will provide the
present status and potential and influence of blinding
on outcomes in general and abdominal surgery RCT.
The study sample included for analysis will be spe-
cific for general and abdominal surgical RCT. To
narrow the analysis on the influence of detection and
performance bias, other sources of biases are
excluded. In the preliminary search, about 30,000 arti-
cles were found. With the above described eligibility
criteria, an estimated precision of 3 % and other
acquainted values from a former review [18, 22], a
sample of about 600 RCT will be expected to be
available for quantitative analysis.
The existing literature clearly shows that existing
detection and performance bias distort the measured
effect from the true effect in pharmacological trials
[7, 12]. In contrast to a pill, surgical interventions
cannot be blinded to all trial contributors. The degree
of such bias in general and abdominal surgery has
never been determined quantitatively. Therefore, the
conduct of this study is important because the know-
ledge about the influence of missing blinding could
further be discussed not only in a qualitative but also
in a quantitative manner. By using the established
Cochrane Collaboration’s tool for assessing risk of
bias [4], the results of the planned analysis will be
specifically applicable to critical appraisal of surgical
trials. Possible overestimated treatment effects could
be detected and corrected or at least be discussed on
quantitative evidence. In case of a missing association
between lack of blinding and significant trial results,
different reasons have to be taken into account. One
reason would be publication bias with due to negative
and assumably blinded trials which were restrained.
Another reason could in fact be the strong physical
component of surgical interventions leading to
unblinding of patients. This reason can be explored if
trials evaluated the unblinding rate of their measures.
However, it is also possible that in surgical trials,
blinding has not the same status than in pharmaco-
logical trials. In case of a true missing association
between lack of blinding and significant trial results,
surgical researcher could rely on this evidence and
leave out complicated ways of blinding methods in
RCT without threatening the validity of trial results.
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